Therakind is attending BIO 2024
Therakind will be attending BIO in San Diego between 3rd and 6th of June. BIO is a renowned conference within the biomedical field that attracts over twenty thousand participants from around the world.
Therakind’s primary aim in BIO this year is to meet potential customers/partners/collaborators for developing dry powder nasal pharmaceutical products. Therakind has a portfolio of dry powder intranasal devices and expertise in formulation development and regulatory strategy. More specifically, Therakind’s novel DriDose Multi-dose Cartridge device is unique as it is reusable and does not require coordinated breathing. We offer a feasibility program, which comprises reformulation and characterisation of a partner’s candidate to evaluate compatibility with Therakind’s nasal device, DriDose.
If you are interested in learning more about the DriDose technology, please reach out to arrange a meeting through the BIO platform:
https://login.partnering.bio.org/inova-business-platform/webclient/#/bio/15601/company/177420
For those interested in partnering with Therakind outside BIO, please contact us at bd@therakind.com
Therakind Contact:
info@therakind.com
Therakind +44 (0) 208 346 6035
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche medicines in difficult-to-treat markets including paediatric and geriatric patient groups. We have successfully brought three products to marketing approval in the EU, UK and US.
Our proprietary pipeline is focused on improving medicine adherence through more patient-friendly dosing options and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. DriDose®, our intranasal device for the delivery of a dry powder drug formulation is available for co-development. We have also developed a device that is adapted for nasal delivery in a preclinical setting.
To find out more, please visit www.therakind.com